How much does a box of Rasagiline cost and price reference by region?

Rasagiline (Rasagiline) is an oral monoamine oxidaseB (MAO-B) inhibitor. It is mainly used for early monotherapy and levodopa combination therapy in advanced patients with Parkinson's disease to improve motor symptoms and delay disease progression. At present, rasagiline has been launched in China and has been included in my country's medical insurance system, which means that patients can purchase it in regular domestic hospital pharmacies and enjoy medical insurance reimbursement. However, the specific reimbursement ratio and co-pay amount vary according to regional policies. It is recommended that patients consult the local hospital or medical insurance department before taking medication.

In the domestic market, the price of rasagiline varies according to specifications and manufacturers. Generally, the price per box ranges from a few hundred yuan to more than a thousand yuan. Because it is included in medical insurance, patients can enjoy a certain percentage of reimbursement when they actually pay out of pocket, thereby reducing medication costs and improving the feasibility of long-term treatment. Medical insurance coverage also makes it easier for rasagiline to be clinically promoted for the long-term management of Parkinson's disease.

In the overseas market, the original drug of rasagiline is mainly the Turkish version, and the price is about 1,000 yuan. In addition, there are Indian versions of generic drugs available, the price of which is only more than 300 yuan, less than half of the original drug. It is worth noting that these generic drugs are basically the same as the original drugs in terms of drug ingredients and efficacy, providing patients with affordable medication options, especially suitable for long-term treatment or patients with limited budgets.

Overall, there are obvious differences in the price of rasagiline in different regions. Domestic listing and inclusion in medical insurance allow patients to obtain drugs at a lower cost, while generic drugs in overseas markets further provide economically viable alternatives. When choosing drug purchasing channels, patients should consider price, medical insurance policies and drug sources to ensure safe and economical access to effective treatment.

Reference link:https://www.drugs.com